Riktkurs.nu
EN | SV
There is a problem with the stock price data. Our supplier is working to solve the issue.
ByggmaxMid CapCamurus
Stockholm Stock Exchange | Mid Cap
Calliditas
+52.44%
Latest
+47.36%
3 months
Kepler CheuvreuxCarnegieSEBPareto SecuritiesGuggenheim SecuritiesBryan GarnierCiti Investment ResearchKempenSEB Equities

Price Targets For Calliditas

AnalystPrice TargetDateUpside
Kepler Cheuvreux150 SEKNov 8
+52.44%
Carnegie140 SEKNov 8
SEB230 SEKJul 31
Pareto Securities230 SEKMay 19
Guggenheim Securities231.05 SEKApr 11
Bryan Garnier190 SEKSep -22
Citi Investment Research384 SEKDec -21
Kempen320 SEKDec -21
SEB Equities75 SEKNov -21

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas

The information on Riktkurs.nu is for general information purposes only. Riktkurs.nu makes no guarantees of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to Riktkurs.nu or the information, products, services, or related information on Riktkurs.nu for any purpose. The recipient is recommended to complete his or her decision basis with the material deemed necessary. We reserve us for all types of errors as well as any malfunctions of the website. The information on Riktkurs.nu should not be seen as a recommendation to buy or sell a security.
© Riktkurs.nu 2023